Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
In this study, we aimed to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) treatment for unresectable hepatocellular carcinoma (HCC) and to analyze the factors affecting overall survival (OS). A total of 69 patients who received Atez/Bev at our institutions for unresecta...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/24/6089 |
| _version_ | 1797461073337516032 |
|---|---|
| author | Shinji Unome Kenji Imai Koji Takai Takao Miwa Tatsunori Hanai Yoichi Nishigaki Hideki Hayashi Takahiro Kochi Shogo Shimizu Junji Nagano Soichi Iritani Atsushi Suetsugu Masahito Shimizu |
| author_facet | Shinji Unome Kenji Imai Koji Takai Takao Miwa Tatsunori Hanai Yoichi Nishigaki Hideki Hayashi Takahiro Kochi Shogo Shimizu Junji Nagano Soichi Iritani Atsushi Suetsugu Masahito Shimizu |
| author_sort | Shinji Unome |
| collection | DOAJ |
| description | In this study, we aimed to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) treatment for unresectable hepatocellular carcinoma (HCC) and to analyze the factors affecting overall survival (OS). A total of 69 patients who received Atez/Bev at our institutions for unresectable HCC were enrolled in this study. OS and progression-free survival (PFS) were estimated using the Kaplan–Meier method. Changes in clinical indicators within 3 months were defined as delta (∆) values, and the Cox proportional hazards model was used to identify which ∆ values affected OS. The median OS, PFS, objective response rate, and disease control rate were 12.5 months, 5.4 months, 23.8%, and 71.4%, respectively. During the observational period, 62 patients (92.5%) experienced AEs (hypertension (33.3%) and general fatigue), and 27 patients (47.4%) experienced grade ≥ 3 AEs (hypertension (10.1%) and anemia (7.2%)). There was a significant deterioration in the albumin-bilirubin (ALBI) score (−2.22 to −1.97; <i>p</i> < 0.001), and a reduction in PIVKA-II levels (32,458 to 11,584 mAU/mL; <i>p</i> = 0.040) within 3 months after commencing Atez/Bev. Both the worsening ∆ ALBI score (<i>p</i> = 0.005) and increasing ∆ PIVKA-II (<i>p</i> = 0.049) were significantly associated with the OS of patients. |
| first_indexed | 2024-03-09T17:14:14Z |
| format | Article |
| id | doaj.art-475b4ff57e4a477bbdbda892973d2997 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T17:14:14Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-475b4ff57e4a477bbdbda892973d29972023-11-24T13:45:58ZengMDPI AGCancers2072-66942022-12-011424608910.3390/cancers14246089Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular CarcinomaShinji Unome0Kenji Imai1Koji Takai2Takao Miwa3Tatsunori Hanai4Yoichi Nishigaki5Hideki Hayashi6Takahiro Kochi7Shogo Shimizu8Junji Nagano9Soichi Iritani10Atsushi Suetsugu11Masahito Shimizu12Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu 501-1194, JapanDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu 501-1194, JapanDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu 501-1194, JapanDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu 501-1194, JapanDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu 501-1194, JapanGifu Municipal Hospital, Gifu 500-8513, JapanGifu Municipal Hospital, Gifu 500-8513, JapanGifu Municipal Hospital, Gifu 500-8513, JapanGifu Prefectural General Medical Center, Gifu 500-8717, JapanGifu Prefectural General Medical Center, Gifu 500-8717, JapanGifu Prefectural General Medical Center, Gifu 500-8717, JapanDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu 501-1194, JapanDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu 501-1194, JapanIn this study, we aimed to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) treatment for unresectable hepatocellular carcinoma (HCC) and to analyze the factors affecting overall survival (OS). A total of 69 patients who received Atez/Bev at our institutions for unresectable HCC were enrolled in this study. OS and progression-free survival (PFS) were estimated using the Kaplan–Meier method. Changes in clinical indicators within 3 months were defined as delta (∆) values, and the Cox proportional hazards model was used to identify which ∆ values affected OS. The median OS, PFS, objective response rate, and disease control rate were 12.5 months, 5.4 months, 23.8%, and 71.4%, respectively. During the observational period, 62 patients (92.5%) experienced AEs (hypertension (33.3%) and general fatigue), and 27 patients (47.4%) experienced grade ≥ 3 AEs (hypertension (10.1%) and anemia (7.2%)). There was a significant deterioration in the albumin-bilirubin (ALBI) score (−2.22 to −1.97; <i>p</i> < 0.001), and a reduction in PIVKA-II levels (32,458 to 11,584 mAU/mL; <i>p</i> = 0.040) within 3 months after commencing Atez/Bev. Both the worsening ∆ ALBI score (<i>p</i> = 0.005) and increasing ∆ PIVKA-II (<i>p</i> = 0.049) were significantly associated with the OS of patients.https://www.mdpi.com/2072-6694/14/24/6089hepatocellular carcinomaatezolizumabbevacizumabprognosis factorALBI scorePIVKA-II |
| spellingShingle | Shinji Unome Kenji Imai Koji Takai Takao Miwa Tatsunori Hanai Yoichi Nishigaki Hideki Hayashi Takahiro Kochi Shogo Shimizu Junji Nagano Soichi Iritani Atsushi Suetsugu Masahito Shimizu Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Cancers hepatocellular carcinoma atezolizumab bevacizumab prognosis factor ALBI score PIVKA-II |
| title | Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma |
| title_full | Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma |
| title_fullStr | Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma |
| title_full_unstemmed | Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma |
| title_short | Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma |
| title_sort | changes in albi score and pivka ii within three months after commencing atezolizumab plus bevacizumab treatment affect overall survival in patients with unresectable hepatocellular carcinoma |
| topic | hepatocellular carcinoma atezolizumab bevacizumab prognosis factor ALBI score PIVKA-II |
| url | https://www.mdpi.com/2072-6694/14/24/6089 |
| work_keys_str_mv | AT shinjiunome changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT kenjiimai changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT kojitakai changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT takaomiwa changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT tatsunorihanai changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT yoichinishigaki changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT hidekihayashi changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT takahirokochi changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT shogoshimizu changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT junjinagano changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT soichiiritani changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT atsushisuetsugu changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma AT masahitoshimizu changesinalbiscoreandpivkaiiwithinthreemonthsaftercommencingatezolizumabplusbevacizumabtreatmentaffectoverallsurvivalinpatientswithunresectablehepatocellularcarcinoma |